Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Subject: search.filters.subject.COVID-19 vaccine

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021
    (ELSEVIER, 2022-01-01) Turco, Fabio; Armstrong, Andrew; Attard, Gerhardt; Beer, Tomasz M.; Beltran, Himisha; Bjartell, Anders; Bossi, Alberto; Briganti, Alberto; Bristow, Rob G.; Bulbul, Muhammad; Caffo, Orazio; Chi, Kim N.; Clarke, Caroline; Clarke, Noel; Davis, Ian D.; de Bono, Johann; Duran, Ignacio; Eeles, Ros; Efstathiou, Eleni; Efstathiou, Jason; Evans, Christopher P.; Fanti, Stefano; Feng, Felix Y.; Fizazi, Karim; Frydenberg, Mark; George, Dan; Gleave, Martin; Halabi, Susan; Heinrich, Daniel; Higano, Celestia; Hofman, Michael S.; Hussain, Maha; James, Nicholas; Jones, Rob; Kanesvaran, Ravindran; Khauli, Raja B.; Klotz, Laurence; Leibowitz, Raya; Logothetis, Christopher; Maluf, Fernando; Millman, Robin; Morgans, Alicia K.; Morris, Michael J.; Mottet, Nicolas; Mrabti, Hind; Murphy, Declan G.; Murthy, Vedang; Oh, William K.; Onyeanunam, Ngozi Ekeke; Ost, Piet; O'Sullivan, Joe M.; Padhani, Anwar R.; Parker, Christopher; Poon, Darren M. C.; Pritchard, Colin C.; Rabah, Danny M.; Rathkopf, Dana; Reiter, Robert E.; Rubin, Mark; Ryan, Charles J.; Saad, Fred; Pablo Sade, Juan; Sartor, Oliver; Scher I, Howard; Shore, Neal; Skoneczna, Iwona; Small, Eric; Smith, Matthew; Soule, Howard; Spratt, Daniel; Sternberg, Cora N.; Suzuki, Hiroyoshi; Sweeney, Christopher; Sydes, Matthew; Taplin, Mary-Ellen; Tilki, Derya; Tombal, Bertrand; Turkeri, Levent; Uemura, Hiroji; Uemura, Hirotsugu; van Oort, Inge; Yamoah, Kosj; Ye, Dingwei; Zapatero, Almudena; Gillessen, Silke; Omlin, Aurelius
    Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70\% of the panellists before the vaccination was available but only for 25\% of panellists for fully vaccinated patients. Most experts (71\%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77\%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55\% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients. (c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • No Thumbnail Available
    Item
    COVID-19 vaccine candidates and vaccine development platforms available worldwide
    (ELSEVIER, 2021-01-01) Duman, Nilgun; ALzaidi, Zahraa; Aynekin, Busra; Taskin, Duygu; Demirors, Busra; Yildirim, Abdulbaki; Sahin, Izem Olcay; Bilgili, Faik; Turanli, Eda Tahir; Beccari, Tommaso; Bertelli, Matteo; Dundar, Munis
    The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombi-nation, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or cer-tification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development. (c) 2021 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • Thumbnail Image
    Item
    The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic
    (SAGE PUBLICATIONS LTD, 2022-01-01) Ekizoglu, Esme; Gezegen, Hasim; Yalinay Dikmen, Pinar; Orhan, Elif Kocasoy; Ertas, Mustafa; Baykan, Betul
    Introduction Headache is a frequent adverse event after viral vaccines. We aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache. Methods The characteristics, associations of this headache, main comorbidities, headache history following the influenza vaccine and during COVID-19 were investigated using a web-based questionnaire. Results A total of 1819 healthcare personnel (mean age: 44.4 +/- 13.4 years, 1222 females), vaccinated with inactivated virus, contributed to the survey